Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €1.11 EUR
Change Today +0.055 / 5.24%
Volume 0.0
O8Z1 On Other Exchanges
O8Z1 is not on other exchanges.
As of 1:27 PM 10/5/15 All times are local (Market data is delayed by at least 15 minutes).

oculus innovative sciences i (O8Z1) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/9/15 - €1.88
52 Week Low
05/7/15 - €0.57
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

oculus innovative sciences i (O8Z1) Related Businessweek News

No Related Businessweek News Found

oculus innovative sciences i (O8Z1) Details

Oculus Innovative Sciences, Inc. designs, produces, and markets prescription and over-the-counter products based on its Microcyn platform technology for the dermatology, surgical, advanced tissue and skin care, and animal healthcare markets in the United States, Mexico, Europe, and internationally. The Microcyn platform technology is based on electrically charged oxychlorine small molecules, which are designed to target a range of pathogens that cause disease, including viruses, fungi, spores, and antibiotic-resistant strains of bacteria, such as methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus, as well as Clostridium difficile, a highly contagious bacteria spread by human contact. It offers Microcyn-based human dermatology and advanced tissue care products as prescription and over-the-counter products; and Microcyn technology-based animal healthcare products under the Vetericyn brand. The company’s Microcyn has received ten 510(k) clearances for use as a medical device in wound care management, including for acute and chronic wounds, and in dermatology applications. In addition, it provides consulting and laboratory services to medical companies that design and manufacture biomedical devices and drugs. Oculus Innovative Sciences, Inc. sells its products directly to third parties, and through contract sales organization and distributors to hospitals, physicians, nurses, and other healthcare practitioners, as well as to dermatologists for the treatment of various skin afflictions. The company was formerly known as Micromed Laboratories, Inc. and changed its name to Oculus Innovative Sciences, Inc. in August 2001. Oculus Innovative Sciences, Inc. was incorporated in 1999 and is headquartered in Petaluma, California.

34 Employees
Last Reported Date: 07/29/15
Founded in 1999

oculus innovative sciences i (O8Z1) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $250.0K
Chief Operating Officer, Chief Financial Offi...
Total Annual Compensation: $250.0K
Executive Vice President of Research and Deve...
Total Annual Compensation: $235.0K
Executive Vice President of International Ope...
Total Annual Compensation: $270.0K
Compensation as of Fiscal Year 2015.

oculus innovative sciences i (O8Z1) Key Developments

Oculus Innovative Sciences Introduces MicrocynAH® Anti-Itch Spray Gel and MicrocynAH® Hot Spot Spray Gel, Dermatology Products for Animals

Oculus Innovative Sciences, Inc. announced the introduction of two new MicrocynAH® dermatology products for animals. MicrocynAH® Anti-Itch Spray Gel and MicrocynAH® Hot Spot Spray Gel both contain the soothing dimethicone skin protectant in combination with the patented Microcyn® Technology, which is supported by 45 patents and over 30 clinical studies worldwide. They effectively help to relieve the pain and itch of skin irritations, lacerations, abrasions and minor burns and are also cleared for the management of irritation and pain from minor sunburn.

Oculus Innovative Sciences, Inc. Announces Introduction of Alevicyn SG Antipruritic Spray Gel for Relief of Pain and Itch in Atopic Dermatitis

Oculus Innovative Sciences, Inc. announced the launch of the company's new Alevicyn SG Antipruritic Spray Gel for the prescription market via the company's dermatology division, IntraDerm Pharmaceuticals. Formulated with the patented Microcyn® Technology, Alevicyn SG Antipruritic Gel is indicated to manage and relieve the burning, itching and pain experienced with various types of dermatoses, including radiation dermatitis and atopic dermatitis. It may be also used to relieve the pain of first- and second-degree burns, and helps to relieve dry waxy skin by maintaining a moist wound and skin environment, which is beneficial to the healing process. Alevicyn SG's unique formulation is a 'spray-on' that does not run or drip after application and no 'rubbing-in' is required on sensitive or difficult-to-access areas of the body. Oculus received FDA 510(k) clearance for the Alevicyn SG in May 2015 and is available nationwide at all chain and independent pharmacies via prescription.

Oculus Innovative Sciences, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended June 30, 2015

Oculus Innovative Sciences, Inc. reported unaudited consolidated earnings results for the first quarter ended June 30, 2015. For the quarter, the company reported total revenues of $3,680,000 against $3,392,000 a year ago. Net loss was $2,340,000 against $70,000 a year ago. Net loss per common basic and diluted share was $0.15 against $0.01 a year ago. Loss from operations was $2,311,000 against $1,514,000 a year ago. The higher net loss was due to a $1.5 million gain due to a change in the fair value of derivative liabilities recognized for the three months ended June 30, 2014, and an increase in sales and marketing costs in the United States for the three months ended June 30, 2015, as compared to the same period in the prior year. Non-GAAP loss from operations minus non-cash expenses was $1,730,000 against $999,000 a year ago. Non-GAAP net loss minus non-cash expenses was $1,700,000 against $1,033,000 a year ago. Non-GAAP loss from operations minus non-cash expenses (LBITDAS) $1,730,000 against $999,000 a year ago. Non-GAAP net loss minus non-cash expenses was $1,700,000 against $1,033,000 a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
O8Z1:GR €1.11 EUR +0.055

O8Z1 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astellas Pharma Inc ¥1,584 JPY +7.00
Henry Schein Inc $138.21 USD +0.57
Integra LifeSciences Holdings Corp $61.21 USD +0.16
Patterson Cos Inc $44.72 USD +0.73
Smith & Nephew PLC 1,169 GBp +27.00
View Industry Companies

Industry Analysis


Industry Average

Valuation O8Z1 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.4x
Price/Book 1.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OCULUS INNOVATIVE SCIENCES I, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at